SCA
VKTX icon

Snowden Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Snowden Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
8,149
+1,282
+19% +$41.4K 0.01% 1046
2026
Q1 		$223K Buy
6,867
+551
+9% +$17.7K 0.01% 1166
2025
Q4 		$222K Buy
+6,316
New +$224K 0.01% 1173
2024
Q4 		– Sell
-4,543
Closed -$288K – 1264
2024
Q3 		$288K Buy
+4,543
New +$267K 0.01% 1011
2022
Q1 		– Sell
-2,400
Closed -$11K – 2022
2021
Q4 		$11K Buy
+2,400
New +$13.5K ﹤0.01% 1499

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Snowden Capital Advisors's VKTX Position: Q2 2026 in Review

Snowden Capital Advisors increased its Viking Therapeutics (VKTX) stake by 19% in Q2 2026, buying an estimated $41.4K and bringing the position to 8,149 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #1046.

Snowden Capital Advisors first reported a position in VKTX in Q4 2021 and has held it in 5 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Snowden Capital Advisors held 8,149 shares of Viking Therapeutics worth $318K as of Q2 2026.
  • Snowden Capital Advisors bought 1,282 Viking Therapeutics shares in Q2 2026, an estimated $41.4K.
  • Viking Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1046 holding.
  • Snowden Capital Advisors first reported a position in Viking Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.